EP4046640A1 — Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders
Assigned to Rotalec IP Holdings LLC · Expires 2022-08-24 · 4y expired
What this patent protects
Provided herein is a pharmaceutical composition comprising cytarabine and daunorubicin at a fixed, non-antagonistic molar ratio encapsulated in liposomes for use in the treatment of patients with hematologic disorders.
USPTO Abstract
Provided herein is a pharmaceutical composition comprising cytarabine and daunorubicin at a fixed, non-antagonistic molar ratio encapsulated in liposomes for use in the treatment of patients with hematologic disorders.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.